- Home
- AVY vs BAX Comparison
AVY vs BAX Comparison
Compare AVY & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVY
- BAX
- Stock Information
- Founded
- AVY 1935
- BAX 1931
- Country
- AVY United States
- BAX United States
- Employees
- AVY N/A
- BAX N/A
- Industry
- AVY Containers/Packaging
- BAX Medical/Dental Instruments
- Sector
- AVY Consumer Discretionary
- BAX Health Care
- Exchange
- AVY Nasdaq
- BAX Nasdaq
- Market Cap
- AVY 16.8B
- BAX 17.3B
- IPO Year
- AVY N/A
- BAX N/A
- Fundamental
- Price
- AVY $201.95
- BAX $33.22
- Analyst Decision
- AVY Buy
- BAX Hold
- Analyst Count
- AVY 12
- BAX 10
- Target Price
- AVY $242.72
- BAX $41.40
- AVG Volume (30 Days)
- AVY 497.9K
- BAX 4.3M
- Earning Date
- AVY 10-23-2024
- BAX 11-08-2024
- Dividend Yield
- AVY 1.74%
- BAX 3.49%
- EPS Growth
- AVY 40.44
- BAX N/A
- EPS
- AVY 8.33
- BAX 0.21
- Revenue
- AVY $8,680,500,000.00
- BAX $15,062,000,000.00
- Revenue This Year
- AVY $5.94
- BAX $3.81
- Revenue Next Year
- AVY $4.86
- BAX $3.45
- P/E Ratio
- AVY $24.33
- BAX $156.31
- Revenue Growth
- AVY 4.84
- BAX 32.37
- 52 Week Low
- AVY $187.93
- BAX $31.60
- 52 Week High
- AVY $233.48
- BAX $44.01
- Technical
- Relative Strength Index (RSI)
- AVY 36.75
- BAX 38.61
- Support Level
- AVY $195.59
- BAX $31.76
- Resistance Level
- AVY $209.83
- BAX $33.22
- Average True Range (ATR)
- AVY 3.08
- BAX 1.00
- MACD
- AVY -0.28
- BAX -0.06
- Stochastic Oscillator
- AVY 28.30
- BAX 30.94
About AVY Avery Dennison Corporation
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification, or RFID, inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.
About BAX Baxter International Inc.
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment, including hospital beds, to the portfolio, although about half of Hillrom's revenue comes from more digitally connected offerings like its smart beds and Voalte medical communications app. From its legacy operations, Baxter sells a variety of injectable therapies for use in care settings, such as IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. It has signed an agreement to sell its kidney care segment by early 2025.